Literature DB >> 15800323

Outcome results of the 1996-1999 patterns of care survey of the national practice for patients receiving radiation therapy for carcinoma of the esophagus.

Mohan Suntharalingam1, Jennifer Moughan, Lawrence R Coia, Mark J Krasna, Lisa Kachnic, Daniel G Haller, Christopher G Willet, Madhu J John, Bruce D Minsky, Jean B Owen.   

Abstract

PURPOSE: A Patterns of Care Study of patients treated from 1996 to 1999 evaluated the national practice for patients receiving radiation therapy for carcinoma of the esophagus in the United States.
METHODS: A national survey was conducted at 59 institutions in a stratified random sample selected from a master list of radiation therapy facilities throughout the United States. Patient, tumor, and treatment characteristics were evaluated. Multivariate comparisons of survival times were made using the Cox proportional hazards model.
RESULTS: Adenocarcinoma was diagnosed in 51% of patients and squamous cell carcinoma in 49% of patients. Sixteen percent of patients were clinical stage (CS) I (using the 1983 American Joint Committee on Cancer system), 39% were CS II, and 33% were CS III. Significant variables in the multivariate analysis of survival times included clinical stage, treatment approach, and facility size. Patients with CS III disease had a higher hazard risk of death as compared with CS I patients (hazard ratio [HR], 2.01; P = .001), whereas those treated with chemoradiotherapy followed by surgery (HR, 0.32; P < .0001) had a decreased risk of death compared with chemoradiotherapy-only patients. Patients at small centers had a higher risk of death (HR, 1.32; P = .03) compared with patients treated at larger facilities.
CONCLUSION: Concurrent chemoradiotherapy continued to be the most commonly utilized treatment approach during the time period studied. The observation that patients undergoing surgical resection following chemoradiation have a decreased HR or chance of death compared with other treatment schemes supports the need for a randomized trial comparing these strategies.

Entities:  

Mesh:

Year:  2005        PMID: 15800323     DOI: 10.1200/JCO.2005.00.448

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  10 in total

1.  The effects of neoadjuvant chemoradiation on pTNM staging and its prognostic significance in esophageal cancer.

Authors:  Simon Law; Dora L W Kwong; Kam-Ho Wong; Ka-Fai Kwok; John Wong
Journal:  J Gastrointest Surg       Date:  2006-11       Impact factor: 3.452

2.  [Palliative options for esophageal carcinoma].

Authors:  F Hagenmüller
Journal:  Chirurg       Date:  2005-11       Impact factor: 0.955

Review 3.  Present status and progress of neoadjuvant chemoradiotherapy for esophageal cancer.

Authors:  Jing Liu; Jinbo Yue; Ligang Xing; Jinming Yu
Journal:  Front Med       Date:  2013-05-17       Impact factor: 4.592

4.  Combined modality therapy of cT2N0M0 esophageal cancer: the University of Texas M. D. Anderson Cancer Center experience.

Authors:  Panteleimon Kountourakis; Arlene M Correa; Wayne L Hofstetter; Jeffrey H Lee; Manoop S Bhutani; David C Rice; Ritsuko Komaki; Dipen M Maru; William A Ross; Ara Vaporciyan; Stephen G Swisher; Jaffer A Ajani
Journal:  Cancer       Date:  2010-10-19       Impact factor: 6.860

5.  The use of neoadjuvant therapy for resectable locally advanced thoracic esophageal squamous cell carcinoma in an analysis of 5016 patients from 305 designated cancer care hospitals in Japan.

Authors:  Yoichiro Tsukada; Takahiro Higashi; Hideaki Shimada; Yoshinori Kikuchi; Atsuro Terahara
Journal:  Int J Clin Oncol       Date:  2017-08-09       Impact factor: 3.402

6.  Stage-specific survival differences associated with postoperative radiotherapy for gastrointestinal cancers.

Authors:  John S Moody; Stephen M Sawrie; Kevin R Kozak; John P Plastaras; George Howard; James A Bonner
Journal:  J Gastrointest Cancer       Date:  2009-03-18

7.  Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer.

Authors:  Ligang Xing; Yemin Liang; Jiandong Zhang; Peipei Wu; Deguo Xu; Fengjun Liu; Xinshuang Yu; Zhongmin Jiang; Xiaoming Song; Qi Zang; Wei Wang
Journal:  J Cancer Res Clin Oncol       Date:  2014-03-01       Impact factor: 4.553

8.  Treatment and survival in a population-based sample of patients diagnosed with gastroesophageal adenocarcinoma.

Authors:  Deirdre P Cronin-Fenton; Margaret M Mooney; Limin X Clegg; Linda C Harlan
Journal:  World J Gastroenterol       Date:  2008-05-28       Impact factor: 5.742

9.  Treatment selection for esophageal cancer: evaluation from a nationwide database.

Authors:  Yasuo Hamamoto; Naoki Sakakibara; Fumio Nagashima; Yuko Kitagawa; Takahiro Higashi
Journal:  Esophagus       Date:  2018-02-20       Impact factor: 4.230

10.  Association between psychological distress of each points of the treatment of esophageal cancer and stress coping strategy.

Authors:  Yu Ohkura; Kanako Ichikura; Junichi Shindoh; Masaki Ueno; Harushi Udagawa; Eisuke Matsushima
Journal:  BMC Psychol       Date:  2022-09-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.